In this study we address two issues regarding serologic immunoassay measurements for CeD: (i) the reestablishment of seropositivity for CeD patients who resume a gluten-containing diet and (ii) the correlation between two different tTG-IgA assays near the ULN designated thresholds. This evidence concerns the gene TGM2 and cranioectodermal dysplasia.